Patent · US Active

Engineered PD-1 variants

US11352413B2 · kind B2 · utility

0Cited by
2References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 9, 2017
Grant dateJun 7, 2022
Priority date—
Expiry dateMay 9, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.